New oral anticoagulants vs. warfarin treatment: no need for pharmacogenomics?
Author(s): Baker WL(1), Chamberlin KW(1).
Affiliation(s): Author information:
(1)1] Department of Pharmacy Practice, School of Pharmacy, University of
Connecticut, Storrs, Connecticut, USA [2] School of Medicine, University of
Connecticut, Farmington, Connecticut, USA.
Publication date & source: 2014, Clin Pharmacol Ther. , 96(1):17-9
For patients requiring long-term anticoagulation, oral vitamin K antagonists
(VKAs) such as warfarin have overwhelming efficacy data and present significant
challenges. In addition to the potential exposure to numerous drug-drug and
drug-food interactions, patients receiving warfarin require frequent monitoring.
It had been hoped that the integration of pharmacogenomic with clinical
information would improve anticoagulation control with warfarin, but trials have
not supported this aim. Novel oral anticoagulants (NOACs) offer both advantages
and disadvantages and deserve consideration in appropriate patients.
|